WEKO3
アイテム
{"_buckets": {"deposit": "db534bb0-77c5-46d1-89d1-eec0ce35c308"}, "_deposit": {"created_by": 1, "id": "82077", "owners": [1], "pid": {"revision_id": 0, "type": "depid", "value": "82077"}, "status": "published"}, "_oai": {"id": "oai:repo.qst.go.jp:00082077", "sets": ["1"]}, "author_link": ["1011414", "1011416", "1011415", "1011417", "1011419", "1011418", "1011413", "1011412"], "item_8_biblio_info_7": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2020-10", "bibliographicIssueDateType": "Issued"}, "bibliographicPageStart": "37", "bibliographicVolumeNumber": "40", "bibliographic_titles": [{"bibliographic_title": "Inflammation and Regeneration"}]}]}, "item_8_description_5": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "The newly emerging coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in Wuhan, China, but has rapidly spread all over the world. Some COVID-19 patients encounter a severe symptom of acute respiratory distress syndrome (ARDS) with high mortality. This high severity is dependent on a cytokine storm, most likely induced by the interleukin-6 (IL-6) amplifier, which is hyper-activation machinery that regulates the nuclear factor kappa B (NF-κB) pathway and stimulated by the simultaneous activation of IL-6-signal transducer and activator of transcription 3 (STAT3) and NF-κB signaling in non-immune cells including alveolar epithelial cells and endothelial cells. We hypothesize that IL-6-STAT3 signaling is a promising therapeutic target for the cytokine storm in COVID-19, because IL-6 is a major STAT3 stimulator, particularly during inflammation. We herein review the pathogenic mechanism and potential therapeutic targets of ARDS in COVID-19 patients.", "subitem_description_type": "Abstract"}]}, "item_8_relation_14": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type_id": {"subitem_relation_type_id_text": "10.1186/s41232-020-00146-3", "subitem_relation_type_select": "DOI"}}]}, "item_8_relation_17": {"attribute_name": "関連サイト", "attribute_value_mlt": [{"subitem_relation_type_id": {"subitem_relation_type_id_text": "https://inflammregen.biomedcentral.com/articles/10.1186/s41232-020-00146-3", "subitem_relation_type_select": "URI"}}]}, "item_8_source_id_9": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "1880-8190", "subitem_source_identifier_type": "ISSN"}]}, "item_access_right": {"attribute_name": "アクセス権", "attribute_value_mlt": [{"subitem_access_right": "metadata only access", "subitem_access_right_uri": "http://purl.org/coar/access_right/c_14cb"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Hojyo, Shintaro"}], "nameIdentifiers": [{"nameIdentifier": "1011412", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Uchida, Mona"}], "nameIdentifiers": [{"nameIdentifier": "1011413", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kumiko Tanaka"}], "nameIdentifiers": [{"nameIdentifier": "1011414", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Hasebe, Rie"}], "nameIdentifiers": [{"nameIdentifier": "1011415", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tanaka, Yuki"}], "nameIdentifiers": [{"nameIdentifier": "1011416", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Murakami, Masaaki"}], "nameIdentifiers": [{"nameIdentifier": "1011417", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Toshio, Hirano"}], "nameIdentifiers": [{"nameIdentifier": "1011418", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Toshio, Hirano", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "1011419", "nameIdentifierScheme": "WEKO"}]}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "How COVID-19 induces cytokine storm with high mortality", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "How COVID-19 induces cytokine storm with high mortality"}]}, "item_type_id": "8", "owner": "1", "path": ["1"], "permalink_uri": "https://repo.qst.go.jp/records/82077", "pubdate": {"attribute_name": "公開日", "attribute_value": "2021-03-09"}, "publish_date": "2021-03-09", "publish_status": "0", "recid": "82077", "relation": {}, "relation_version_is_last": true, "title": ["How COVID-19 induces cytokine storm with high mortality"], "weko_shared_id": -1}
How COVID-19 induces cytokine storm with high mortality
https://repo.qst.go.jp/records/82077
https://repo.qst.go.jp/records/8207705b6cd3e-ccac-494e-ac9d-2ea5524c694a
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2021-03-09 | |||||
タイトル | ||||||
タイトル | How COVID-19 induces cytokine storm with high mortality | |||||
言語 | ||||||
言語 | eng | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
アクセス権 | ||||||
アクセス権 | metadata only access | |||||
アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
著者 |
Hojyo, Shintaro
× Hojyo, Shintaro× Uchida, Mona× Kumiko Tanaka× Hasebe, Rie× Tanaka, Yuki× Murakami, Masaaki× Toshio, Hirano× Toshio, Hirano |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | The newly emerging coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in Wuhan, China, but has rapidly spread all over the world. Some COVID-19 patients encounter a severe symptom of acute respiratory distress syndrome (ARDS) with high mortality. This high severity is dependent on a cytokine storm, most likely induced by the interleukin-6 (IL-6) amplifier, which is hyper-activation machinery that regulates the nuclear factor kappa B (NF-κB) pathway and stimulated by the simultaneous activation of IL-6-signal transducer and activator of transcription 3 (STAT3) and NF-κB signaling in non-immune cells including alveolar epithelial cells and endothelial cells. We hypothesize that IL-6-STAT3 signaling is a promising therapeutic target for the cytokine storm in COVID-19, because IL-6 is a major STAT3 stimulator, particularly during inflammation. We herein review the pathogenic mechanism and potential therapeutic targets of ARDS in COVID-19 patients. | |||||
書誌情報 |
Inflammation and Regeneration 巻 40, p. 37, 発行日 2020-10 |
|||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 1880-8190 | |||||
DOI | ||||||
識別子タイプ | DOI | |||||
関連識別子 | 10.1186/s41232-020-00146-3 | |||||
関連サイト | ||||||
識別子タイプ | URI | |||||
関連識別子 | https://inflammregen.biomedcentral.com/articles/10.1186/s41232-020-00146-3 |